Unknown

Dataset Information

0

Targeting ?-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations.

ABSTRACT: Progressive neuronal cell loss in a small subset of brainstem and mesencephalic nuclei and widespread aggregation of the ?-synuclein protein in the form of Lewy bodies and Lewy neurites are neuropathological hallmarks of Parkinson's disease. Most cases occur sporadically, but mutations in several genes, including SNCA, which encodes ?-synuclein, are associated with disease development. The discovery and development of therapeutic strategies to block cell death in Parkinson's disease has been limited by a lack of understanding of the mechanisms driving neurodegeneration. However, increasing evidence of multiple pivotal roles of ?-synuclein in the pathogenesis of Parkinson's disease has led researchers to consider the therapeutic potential of several strategies aimed at reduction of ?-synuclein toxicity. We critically assess the potential of experimental therapies targeting ?-synuclein, and discuss steps that need to be taken for target validation and drug development.

SUBMITTER: Dehay B 

PROVIDER: S-EPMC5217462 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations.

Dehay Benjamin B   Bourdenx Mathieu M   Gorry Philippe P   Przedborski Serge S   Vila Miquel M   Hunot Stephane S   Singleton Andrew A   Olanow C Warren CW   Merchant Kalpana M KM   Bezard Erwan E   Petsko Gregory A GA   Meissner Wassilios G WG  

The Lancet. Neurology 20150603 8

Progressive neuronal cell loss in a small subset of brainstem and mesencephalic nuclei and widespread aggregation of the α-synuclein protein in the form of Lewy bodies and Lewy neurites are neuropathological hallmarks of Parkinson's disease. Most cases occur sporadically, but mutations in several genes, including SNCA, which encodes α-synuclein, are associated with disease development. The discovery and development of therapeutic strategies to block cell death in Parkinson's disease has been lim  ...[more]

Similar Datasets

Unknown Emerging disease-modifying strategies targeting α-synuclein for the treatment of Parkinson's disease.
| S-EPMC6031880 | biostudies-literature
Unknown Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease.
| S-EPMC6906193 | biostudies-literature
Unknown Rationale for therapeutic silencing of alpha-synuclein in Parkinson's disease.
| S-EPMC4027709 | biostudies-literature
Unknown Therapeutic functions of astrocytes to treat α-synuclein pathology in Parkinson's disease.
| S-EPMC9304026 | biostudies-literature
Unknown Alpha-synuclein and familial Parkinson's disease.
| S-EPMC3397145 | biostudies-literature
Unknown Alpha-Synuclein Aggregation in Parkinson's Disease.
| S-EPMC8558257 | biostudies-literature
Unknown Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease.
| S-EPMC3925190 | biostudies-literature
Transcriptomics Mechanistic impacts of bacterial diet on dopaminergic neurodegeneration in a Caenorhabditis elegans α-synuclein model of Parkinson's disease
2023-05-19 | GSE210005 | GEO
Unknown Mechanistic basis for receptor-mediated pathological α-synuclein fibril cell-to-cell transmission in Parkinson's disease.
| S-EPMC8256039 | biostudies-literature
Unknown A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.
| S-EPMC5840882 | biostudies-literature